scholarly journals Pregnancy outcome in women with antiphospholipid syndrome on low-dose aspirin and heparin: a retrospective study

2010 ◽  
Vol 16 (03) ◽  
pp. 308-312 ◽  
Author(s):  
T. Naru ◽  
R.S. Khan ◽  
R. Ali
Keyword(s):  
Retrospective Study ◽  
Pregnancy Outcome ◽  
Antiphospholipid Syndrome ◽  
Low Dose ◽  
Dose Aspirin ◽  
Low Dose Aspirin

scholarly journals Successful Pregnancy Outcome in a Patient with Antiphospholipid Syndrome : A Case Report

2013 ◽  
Vol 3 (1) ◽  
pp. 44-46
Author(s):  
Hasna Fahmima Haque ◽  
Muhammad Abdur Rahim ◽  
Mohammad Gaffar Amin ◽  
Shahana Zaman ◽  
Pratik Dewan ◽  
...  
Keyword(s):  
Pregnancy Outcome ◽  
Antiphospholipid Syndrome ◽  
Pregnancy Loss ◽  
Low Dose ◽  
Recurrent Pregnancy Loss ◽  
Fetal Loss ◽  
Successful Pregnancy ◽  
Dose Aspirin ◽  
Low Dose Aspirin ◽  
High Index Of Suspicion

Antiphospholipid syndrome (APS) manifests clinically as recurrent venous or arterial thrombosis and/or fetal loss. Diagnosis requires a high index of suspicion during evaluation of women with recurrent pregnancy loss and vascular thrombosis. Low dose aspirin combined with heparin can reduce morbidity and improve the pregnancy outcome. Here we report a case of a 22 year old lady having APS who presented with arthritis, recurrent miscarriages and venous thrombosis. Birdem Med J 2013; 3(1): 44-46 DOI: http://dx.doi.org/10.3329/birdem.v3i1.17126

scholarly journals AB0372 PREGNANCY OUTCOME IN WOMEN WITH SJÖGREN SYNDROME IS OFTEN COMPLICATED BY PLACENTA INSUFFICIENCY

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1486.2-1486
Author(s):  
I. Troester ◽  
F. Kollert ◽  
A. Zbinden ◽  
L. Raio ◽  
F. Foerger
Keyword(s):  
Pregnancy Outcome ◽  
Preterm Delivery ◽  
Gestational Age ◽  
Small For Gestational Age ◽  
Low Dose ◽  
Sjögren Syndrome ◽  
Sjogren Syndrome ◽  
Live Births ◽  
Dose Aspirin ◽  
Low Dose Aspirin

Background:Chronic inflammatory rheumatic diseases are often associated with a negative effect on pregnancy outcome. Most obstetrical complications are placenta-mediated such as preterm delivery and growths restrictions. In women with Sjögren syndrome, data on placenta- mediated complications are scarce and conflicting (1,2).Objectives:To analyse neonatal outcome in women with Sjögren syndrome with focus on preterm delivery and growth restriction.Methods:We retrospectively analysed 23 pregnancies of 16 patients with Sjögren syndrome that were followed at our centre with regard to pregnancy outcome, medication and disease characteristics. Small for gestational age was defined as birthweight percentile <10th. Preterm delivery was defined as delivery before 37, early term as delivery between 37-39 and term as delivery between 39-42 weeks of gestation.Results:Of 23 pregnancies, one ended in a miscarriage and 22 resulted in live births including one set of twins. Treatment used during pregnancy was hydroxychloroquine (20 pregnancies), prednisone (8), azathioprine (5) and cyclosporine (2). Concomitant treatment with low-dose aspirin was used in 9 pregnancies.Of the 22 live births, 17 were born at early term and 5 at term. There were no preterm deliveries. Median birth weight was 2820g (range 2095-3845g). Nine newborns (40.9%) were small for gestational age (SGA). Maternal treatment during these pregnancies was hydroxychloroquine in all cases and additional low-dose aspirin in three cases. Elevated CRP levels during pregnancy were found in 57% of the cases with SGA outcome. Only one woman with an SGA infant had positive anti-phospholipid antibodies.Regarding delivery mode, most patients had caesarean sections.Conclusion:In our cohort of women with Sjögren syndrome the prevalence of small for gestational age infants was high despite maternal treatment with hydroxychloroquine. Inflammatory markers could help to identify the patients at risk for placental insufficiency, yet prospective studies of larger cohorts are needed.References:[1]Gupta S et al; Sjögren Syndrome and Pregnancy: A literature review. Perm J 2017; 21:16-047[2]De Carolis S et al; The impact of primary Sjögren’s syndrome on pregnancy outcome: Our series and review of the literature. Autoimmun Rev 2014; 13(2):103-7Disclosure of Interests:Isabella Troester: None declared, Florian Kollert Employee of: Novartis, Astrid Zbinden: None declared, Luigi Raio: None declared, Frauke Foerger Grant/research support from: unrestricted grant from UCB, Consultant of: UCB, GSK, Roche, Speakers bureau: UCB, GSK

scholarly journals Digital ischaemia secondary to adalimumab-induced antiphospholipid syndrome

2020 ◽  
Vol 13 (2) ◽  
pp. e232907 ◽  
Author(s):  
Shashank Cheemalavagu ◽  
Sara S McCoy ◽  
Jason S Knight
Keyword(s):  
Antiphospholipid Syndrome ◽  
Low Dose ◽  
Antiphospholipid Antibody ◽  
Antibody Testing ◽  
Left Hand ◽  
Dose Aspirin ◽  
Low Dose Aspirin ◽  
History Of ◽  
Digital Ischaemia ◽  
Necrosis Factor

A 50-year-old woman with a history of Crohn’s disease treated with adalimumab presented with left hand pain and duskiness. Angiogram showed non-filling of the radial and digital arteries of the hand. Antiphospholipid antibody testing was positive, leading to a diagnosis of antitumour necrosis factor-induced antiphospholipid syndrome. Adalimumab was discontinued, and she was treated with the vitamin K antagonist warfarin and low-dose aspirin. Upon resolution of the antiphospholipid antibodies, she was transitioned to aspirin alone without recurrence of thrombosis.

Stillbirth: the impact of antiphospholipid syndrome?

Lupus ◽  
2016 ◽  
Vol 26 (3) ◽  
pp. 237-239 ◽  
Author(s):  
C A Herrera ◽  
C C Heuser ◽  
D Ware Branch
Keyword(s):  
Antiphospholipid Syndrome ◽  
Antiphospholipid Antibodies ◽  
Lupus Anticoagulant ◽  
Low Dose ◽  
Fetal Death ◽  
Therapeutic Approaches ◽  
New Therapeutic Approaches ◽  
Dose Aspirin ◽  
Low Dose Aspirin ◽  
The Impact

Fetal death resulting in stillbirth is generally acknowledged as a feature of antiphospholipid syndrome. Recently published studies appear to confirm the association between antiphospholipid antibodies (aPL) and stillbirth, though additional studies of better design would be welcome. Emerging evidence suggests that treatment with heparin agents and low dose aspirin to prevent fetal death is imperfect. New therapeutic approaches for patients with lupus anticoagulant or triple aPL positivity are needed.

Low dose aspirin after ischemic stroke associated with antiphospholipid syndrome

Neurology ◽  
2003 ◽  
Vol 61 (1) ◽  
pp. 111-114 ◽  
Author(s):  
R.H.W.M. Derksen ◽  
P.G. de Groot ◽  
L.J. Kappelle
Keyword(s):  
Ischemic Stroke ◽  
Antiphospholipid Syndrome ◽  
Low Dose ◽  
Dose Aspirin ◽  
Low Dose Aspirin

Combined Antithrombotic Therapy but Not Single-Agent Therapy with Low-Dose Aspirin Deteriorated Platelet Activation in Patients with Antiphospholipid Syndrome (APS).

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 4002-4002 ◽  
Author(s):  
Masahide Yamazaki ◽  
Yasuko Kadohira ◽  
Eriko Morishita ◽  
Hidesaku Asakura ◽  
Shinji Nakao
Keyword(s):  
Platelet Activation ◽  
Antiphospholipid Syndrome ◽  
Plasma Levels ◽  
Antithrombotic Therapy ◽  
Low Dose ◽  
Single Agent ◽  
Dose Aspirin ◽  
Low Dose Aspirin ◽  
Group A ◽  
Group B

Abstract Antiphospholipid syndrome (APS) is one of autoimmune disorders characterized with recurrent thromboses. It is considered that plasma levels of D-dimer and prothrombin fragment 1+2 (F1+2) could reflect hypercoagulable state in APS patients and those monitoring may be useful for a predictor of venous thromboses. In contrast, the estimation of platelet activation is difficult. Recently, plasma levels of platelet-derived microparticle (PDMP), which released from activated platelets, could be measured using ELISA supplied from JIMRO Co. JAPN (“JIMRO test PDMP”). We previously presented that plasma levels of PDMP were significantly elevated in APS-patients with arterial thromboses and that could reflect platelet activated condition in vivo. To evaluate the preventory effect of thromboses and the inhibitory effects for platelet activation by several kinds of antithrombotic agents in APS, 30 APS patients with cerebral infarctions were randomly treated with low-dose aspirin alone (Group A, n=10), aspirin plus warfarin (Group B, n=10), or aspirin plus cirostazole (Group C, n=10). Their plasma PDMP levels were measured using “JIMRO test PDMP” (JIMRO Co., JAPAN) before and after antithromboitic treatment on a regular schedule, and MRI brain scans were also underwent in every six months. Plasma PDMP levels in group B and group C significantly decreased by combined antithrombotic therapy (18.0 ± 7.1 to 13.0 ± 8.2 U/mL, 17.8 ± 6.7 to 12.4 ± 7.8 U/mL, p &lt; 0.03 and &lt; 0.01, respectively) but not in Group A (18.2 ± 8.1 to 17.9 ± 9.1, NS). Brain MRI revealed worsening of lacuna infarctions in only one patient in Group A. No serious adverse effects were shown in any patients. These findings suggest that single use of aspirin could be enough for prevention of arterial thrombosis in APS patients and that plasma PDMP levels may be useful for an indicator of antiplatelet therapy.

Maternal serum thromboxane B2 reduction versus pregnancy outcome in a low-dose aspirin trial

1995 ◽  
Vol 173 (2) ◽  
pp. 578-584 ◽  
Author(s):  
John C. Hauth ◽  
Robert L. Goldenberg ◽  
G.Richard Parker ◽  
Rachel L. Copper ◽  
Gary R. Cutter
Keyword(s):  
Pregnancy Outcome ◽  
Low Dose ◽  
Maternal Serum ◽  
Thromboxane B2 ◽  
Dose Aspirin ◽  
Low Dose Aspirin ◽  
Serum Thromboxane
Sign in / Sign up

Export Citation Format

Share Document